NCT05413850 2026-03-02
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT05939414 2026-02-24
PSMA-DC
Novartis
Phase 3 Recruiting
NCT07232407 2026-01-07
A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07274852 2026-01-06
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06531499 2025-12-31
RADIODOSE
Novartis
Phase 1 Recruiting
NCT06517719 2025-12-30
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Novartis
Recruiting
NCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT05803941 2025-04-24
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis
Phase 4 Recruiting
NCT04261855 2025-02-14
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Recruiting
NCT06449781 2025-02-10
PSMA-ADJUVO
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting
NCT04949282 2022-12-23
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
Recruiting